Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 10:47 ET | Source: Research and Markets

Chronic Kidney Disease Anemia Market Opportunity Assessment and Forecasts 2024-2034: Drug Costs, Safety Improvements, ESA Alternatives, and Enhanced Clinical Trial Design

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Anemia: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the...
November 18, 2025 09:57 ET | Source: Research and Markets

Nephrotic Syndrome Industry Research 2025-2035: Market Advances with Growing Adoption of SGLT2 Inhibitors and Novel Renoprotective Agents for Proteinuria Reduction and Kidney Function Preservation

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Nephrotic Syndrome Market - A Global and Regional Analysis: Focus on Diagnosis, Treatment, End User, Country, and Region - Analysis and Forecast,...
November 05, 2025 02:00 ET | Source: Averoa

AVEROA Receives UK MHRA Approval for XOANACYL®, an Oral Therapy Targeting Key Complications of Chronic Kidney Disease (CKD)

The MHRA (Medicines and Healthcare products Regulatory Agency) granted UK Marketing Authorisation for XOANACYL via the International Recognition Procedure (Route B) recognising its prior EU approval...
September 03, 2025 08:19 ET | Source: Biomerica, Inc.

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use

10-minute home test detects early kidney damage in diabetic and hypertensive patientsHypertension affects roughly one-third of adults in the UAEDiabetes impacts approximately one in four UAE nationals...
June 16, 2025 06:00 ET | Source: Averoa

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL for UK approval via MHRA’s International...
April 22, 2025 06:55 ET | Source: Arch Biopartners

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research...
April 17, 2025 08:19 ET | Source: Biomerica, Inc.

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Disease Test for Early Detection of Kidney Damage

Regulatory milestone enables commercial expansion into high-need international market10-minute test detects early signs of kidney damage using a simple urine sample Addresses global public health...
April 08, 2025 07:00 ET | Source: Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease

VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
April 02, 2025 05:00 ET | Source: Averoa

AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemiaFinal European Commission decision...
February 19, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC highlights...